Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PER2 | O15055 | 1/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243199 | 0.91 | HTR1A (0.53) | HTR1AHTR2ATMEM97ADAM17THRB | |
| SCHEMBL5251364 | 0.86 | HTR1A (0.43) | HTR1AHTR2ATMEM97THRBPARP1 | |
| SCHEMBL5250167 | 0.83 | HTR1A (0.60) | HTR1AHTR2ATMEM97PARP1KDM4E | |
| SCHEMBL5247543 | 0.82 | ACHE (0.46) | HTR1AHTR2ATMEM97PARP1 | |
| SCHEMBL5248037 | 0.81 | HTR2A (0.81) | HTR1AHTR2ATMEM97KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5247881 | 0.80 | HTR2A (0.79) | HTR1AHTR2ATMEM97KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5248392 | 0.79 | PARP1 (0.47) | HTR1AHTR2ATMEM97ADAM17PARP1 | |
| SCHEMBL2029501 | 0.79 | HTR1A (0.43) | HTR1AHTR2ATMEM97ADAM17THRB | |
| SCHEMBL5242210 | 0.79 | HTR1A (0.43) | HTR1AHTR2ATMEM97THRBPARP1 | |
| SCHEMBL5248078 | 0.76 | HTR1A (0.46) | HTR1AHTR2ATMEM97PARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1260512-B1 | NOVEL CYCLIC AMIDE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 79/4885HTR2A 153/4885TMEM97 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.